Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Subvisible (2-100 μm) Particle Analysis During Biotherapeutic Drug Product Development: Part 1, Considerations and Strategy.
Narhi LO, Corvari V, Ripple DC, Afonina N, Cecchini I, Defelippis MR, Garidel P, Herre A, Koulov AV, Lubiniecki T, Mahler HC, Mangiagalli P, Nesta D, Perez-Ramirez B, Polozova A, Rossi M, Schmidt R, Simler R, Singh S, Spitznagel TM, Weiskopf A, Wuchner K. Narhi LO, et al. Among authors: afonina n. J Pharm Sci. 2015 Jun;104(6):1899-1908. doi: 10.1002/jps.24437. Epub 2015 Apr 1. J Pharm Sci. 2015. PMID: 25832583 Review.
Subvisible (2-100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis.
Corvari V, Narhi LO, Spitznagel TM, Afonina N, Cao S, Cash P, Cecchini I, DeFelippis MR, Garidel P, Herre A, Koulov AV, Lubiniecki T, Mahler HC, Mangiagalli P, Nesta D, Perez-Ramirez B, Polozova A, Rossi M, Schmidt R, Simler R, Singh S, Weiskopf A, Wuchner K. Corvari V, et al. Among authors: afonina n. Biologicals. 2015 Nov;43(6):457-73. doi: 10.1016/j.biologicals.2015.07.011. Epub 2015 Aug 29. Biologicals. 2015. PMID: 26324466 Review.
A Multicompany Assessment of Submicron Particle Levels by NTA and RMM in a Wide Range of Late-Phase Clinical and Commercial Biotechnology-Derived Protein Products.
Hubert M, Yang DT, Kwok SC, Rios A, Das TK, Patel A, Wuchner K, Antochshuk V, Junge F, Bou-Assaf GM, Cao S, Saggu M, Montrond L, Afonina N, Kolhe P, Loladze V, Narhi L. Hubert M, et al. Among authors: afonina n. J Pharm Sci. 2020 Jan;109(1):830-844. doi: 10.1016/j.xphs.2019.10.025. Epub 2019 Oct 21. J Pharm Sci. 2020. PMID: 31647951
[Vaccine prophylaxis of varicella: tactics and perspectives].
Ermolenko MV, Mikheeva IV, Voronin EM, Saltykova TS, Afonina NM. Ermolenko MV, et al. Among authors: afonina nm. Zh Mikrobiol Epidemiol Immunobiol. 2013 Jan-Feb;(1):85-8. Zh Mikrobiol Epidemiol Immunobiol. 2013. PMID: 23805659 Russian. No abstract available.
14 results